# Palatin Technologies Inc: overview PTN · Nasdaq · CIK 911216 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/ptn.md) · [Financials](/companies/ptn/financials.md) · [Filings](/companies/ptn/filings.md) · [Insiders](/companies/ptn/insiders.md) Latest reported revenue: [$300.8k](/filings/0001493152-26-044572.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 28, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001493152-26-044572). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001654954-25-013091.md) | not reported | [0.0](/filings/0001654954-25-005610.md) | [0.0 d](/filings/0001654954-25-011030.md) | [8,830](/filings/0001493152-26-022778.md) | [116](/filings/0001493152-26-006969.md) | [3,921](/filings/0001493152-26-022778.md) | [301 d](/filings/0001493152-26-044572.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | [52.8%](/filings/0001654954-25-013091.md) | [(6315.8%)](/filings/0001493152-26-006969.md) | [(40.3%)](/filings/0001493152-26-022778.md) | [(1469.5%) d](/filings/0001493152-26-044572.md) | | Net margin | % | not reported | not reported | not reported | not reported | [53.0%](/filings/0001654954-25-013091.md) | [(6260.0%)](/filings/0001493152-26-006969.md) | [(36.5%)](/filings/0001493152-26-022778.md) | [(1449.1%) d](/filings/0001493152-26-044572.md) | | Diluted EPS | $ per share | [(19.71)](/filings/0001654954-25-013091.md) | [(5.92)](/filings/0001493152-26-006969.md) | [(9.13)](/filings/0001493152-26-022778.md) | not reported | [4.26](/filings/0001654954-25-013091.md) | [(2.86)](/filings/0001493152-26-006969.md) | [(0.37)](/filings/0001493152-26-022778.md) | not reported | | Free cash flow | $k | not reported | not reported | [(5,354) d](/filings/0001493152-26-022778.md) | [(4,089) d](/filings/0001493152-26-044572.md) | not reported | not reported | [(4,456) d](/filings/0001493152-26-022778.md) | [(2,690) d](/filings/0001493152-26-044572.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.5](/filings/0001654954-23-012335.md) | [4.9](/filings/0001654954-24-012498.md) | [4.5](/filings/0001654954-25-011030.md) | [0.0](/filings/0001654954-25-011030.md) | [13.2](/filings/0001493152-26-044572.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(2491.6%)](/filings/0001654954-23-012335.md) | [(668.7%)](/filings/0001654954-24-012498.md) | [(501.0%)](/filings/0001654954-25-011030.md) | not reported | [(65.7%)](/filings/0001493152-26-044572.md) | | Net margin | % | [(2465.1%)](/filings/0001654954-23-012335.md) | [(495.2%)](/filings/0001654954-24-012498.md) | [(662.3%)](/filings/0001654954-25-011030.md) | not reported | [(63.5%)](/filings/0001493152-26-044572.md) | | Diluted EPS | $ per share | not reported | not reported | [(101.16)](/filings/0001654954-25-011030.md) | [(32.15)](/filings/0001493152-26-044572.md) | [(2.96)](/filings/0001493152-26-044572.md) | | Free cash flow | $m | [(30.2)](/filings/0001654954-23-012335.md) | [(29.7)](/filings/0001654954-24-012498.md) | [(31.5)](/filings/0001654954-25-011030.md) | [(21.3)](/filings/0001493152-26-044572.md) | [(13.6)](/filings/0001493152-26-044572.md) | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ptn/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANUS HENDERSON GROUP PLC](/funds/1274173.md) | 2026-03-31 | $2.4m | 140,000 | | Not compared | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $1.8m | 166,713 | | Unchanged | | [Jupiter Topco LLC](/funds/2146052.md) | 2026-06-30 | $1.5m | 140,000 | | Not compared | | [Logos Global Management LP](/funds/1792126.md) | 2026-06-30 | $1.4m | 130,000 | | Reduced −10,000 | | [RA CAPITAL MANAGEMENT, L.P.](/funds/1346824.md) | 2026-06-30 | $670.3k | 62,124 | | Reduced −7,876 | | [Balyasny Asset Management L.P.](/funds/1218710.md) | 2026-06-30 | $443.6k | 41,110 | | Reduced −59 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $294.3k | 27,272 | | Unchanged | | [Opaleye Management Inc.](/funds/1595855.md) | 2026-06-30 | $221.2k | 20,500 | | New +20,500 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $209.2k | 19,382 | | Added +880 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $204.1k | 18,911 | | Reduced −68 | ## Recent filings [All 789 filings](/companies/ptn/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-28 | 16:30 ET | [10-K](/filings/0001493152-26-044572.md) | Annual report, period 2026-06-30 | 0001493152-26-044572 | | 2026-08-03 | 06:04 ET | [8-K](/filings/0001493152-26-035722.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001493152-26-035722 | | 2026-06-25 | 16:15 ET | [DEF 14A](/filings/0001493152-26-030126.md) | Proxy statement, period 2026-06-25 | 0001493152-26-030126 | | 2026-05-18 | 17:07 ET | [8-K](/filings/0001493152-26-024219.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-024219 | | 2026-05-13 | 17:00 ET | [10-Q](/filings/0001493152-26-022778.md) | Quarterly report, period 2026-03-31 | 0001493152-26-022778 | | 2026-02-17 | 09:30 ET | [10-Q](/filings/0001493152-26-006969.md) | Quarterly report, period 2025-12-31 | 0001493152-26-006969 | | 2025-12-19 | 16:30 ET | [8-K/A](/filings/0001493152-25-028569.md) | 5.07 Shareholder vote results | 0001493152-25-028569 | | 2025-11-14 | 16:33 ET | [10-Q](/filings/0001654954-25-013091.md) | Quarterly report, period 2025-09-30 | 0001654954-25-013091 | | 2025-11-12 | 16:50 ET | [8-K](/filings/0001654954-25-012928.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-25-012928 | | 2025-11-06 | 08:57 ET | [8-K](/filings/0001654954-25-012641.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001654954-25-012641 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001493152-26-044572.md), filed Sep 28, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/15a0ef34-289e-4cbd-aaa7-22c896b66184) ## About the filer - CIK: 911216 - Tickers: PTN - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NJ - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.